

## Press release

### Treatment of severe heart failure - AI

## FineHeart receives a European grant of €1.5M

*Within the framework of the FEDER-FSE "Nouvelle Aquitaine" 2014-2020 REACT-UE program*

### Dedicated to the development of the implantable mechatronics of the ICOMS FLOWMAKER®

**Bordeaux, France, December 8, 2022** - FineHeart S.A, a medical device company developing the ICOMS FLOWMAKER®, a fully implantable cardiac output restoration system to address the unmet needs of patients suffering from severe heart failure, announced today that it has been awarded €1.5M in funding from the European ERDF/ESF program. This program supports the European Regional Development Fund and the European Social Fund "**Investment for growth and employment in the New Aquitaine Region**".

This grant is awarded to FineHeart to pursue its development of the implantable mechatronics of the ICOMS FLOWMAKER®, an innovative technology, which is designed and developed to meet the programming needs of cardiologists during implantation and for the regular control of implanted patients.

"We are very pleased to receive the support of the New Aquitaine Region, which, as managing agent of European programs, renews its confidence in FineHeart. We are delighted to contribute to the industrial wealth of the New Aquitaine region by developing cutting-edge industrial know-how. We look forward to evaluating the therapeutic potential of the ICOMS FLOWMAKER® during first in human implantation, scheduled in Europe in 2023." said **Arnaud Mascarell, CEO and co-founder of Fineheart**:

#### **About the ERDF program**

The European Regional Development Fund (ERDF) is part of the economic, social and territorial cohesion policy. Its purpose is to strengthen economic and social cohesion in the European Union by correcting imbalances between its regions. In France, for the 2014-2020 period, the ERDF represents 8.4 billion euros devoted to the "investment for growth and employment" objective, with a view to consolidating the labor market and regional economies.

#### **About the ICOMS FLOWMAKER®**

The ICOMS FLOWMAKER® is the first fully intraventricular, wireless flow accelerator that provides physiological support synchronized with the heart's natural contractions. It respects the natural blood flow and does not require aortic bypass surgery. It is the first miniaturized device - barely 10 cm in size - that is adjustable to patients' needs, like a pacemaker, to treat patients with varying degrees of severity. It has no external driveline as it is recharged via a wireless transcutaneous energy transfer system (TET). The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, which, on average lasts 90 minutes.

Second cause of death in the world after cancer, severe heart failure is a degenerative disease that progresses to a severe form, resulting in an inability of the heart to contract effectively. Each year, 200,000 patients are not effectively managed due to lack of treatment.

### **About FineHeart**

FineHeart is a medical device company that is developing its innovative ground-breaking product, ICOMS FLOWMAKER®, with the potential to treat 200,000 patients with severe heart failure each year. First-In-Human trials are expected in 2023. FineHeart will initially target the 50,000 most severe patients who are eligible for cardiac assistance. Initial estimates value this market segment to be worth over US\$5 billion.

Founded in 2010, FineHeart is based in Bordeaux employing close to 50 employees. It is led by a team of internationally renowned cardiac surgeons and electro-physiologists: Dr. Stéphane Garrigue, PhD, CSO co-inventor of ICOMS FLOWMAKER®; Dr. Philippe Ritter, MS, co-inventor of cardiac resynchronization (CRT); and Arnaud Mascarell, FineHeart's CEO. The company holds a portfolio of 72 patents in 18 families.

FineHeart is supported by a wide pool of public and private industrial and independent investors: Lauak Group, Doliam, Med-INNOV, FineHeart Founders' Holding representing domestic and international private investors, mainly from the cardiology sector, and the European investment fund Verve Ventures as well as historical shareholders Irdi, Aquiti, Galia, Broadview Ventures, and M Capital. FineHeart also benefits from the financial support of the European Union, Bpifrance, the New Aquitaine Region and the Centre Region.

---

### **Contacts**

#### **Europe**

#### **Media Relations**

Annie-Florence Loyer  
afloyer@newcap.fr  
+33 (0) 6 88 20 35 59

#### **FineHeart Communications**

James Palmer  
j.palmer@orpheonfinance.com  
+33 (0) 7 60 92 77 72

#### **Helinnov – Conseil en direction financière**

Hélène Cima  
[helene.cima@helinnov.fr](mailto:helene.cima@helinnov.fr)  
+33 (0) 6 99 28 40 80

---

28 Avenue Gustave Eiffel,  
Bâtiment C, 33600 Pessac - FR  
[contact@fine-heart.com](mailto:contact@fine-heart.com)  
+33 5 64 31 18 40